Skip to main content

HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy

CBE ID
0407
1.4 Project
Infectious Disease Endorsement Maintenance
Endorsement Status
Endorsement Removed
1.1 New or Maintenance
Maintenance
Previous Endorsement Cycle
Spring 2013
Is Under Review
No
1.3 Measure Description

Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, who had at least two medical visits during the measurement year, with at least 90 days between each visit, who are receiving potent antiretroviral therapy*, who have a viral load <200 copies/mL after at least 6 months of potent antiretroviral therapy*

*Potent antiretroviral therapy is described as any antiretroviral therapy that has demonstrated optimal efficacy and results in durable suppression of HIV as shown by prior clinical trials

    • 1.14 Numerator

      Patients with an HIV viral load <200 copies/mL

    • 1.15 Denominator

      All patients aged 13 years or older with a diagnosis of HIV/AIDS, with at least two visits in the measurement year, with at least 90 days between each visit, who received potent antiretroviral therapy* for at least 6 months

      Definition of “Medical Visit” - any visit with a health care professional who provides routine primary care for the patient with HIV/AIDS (may be but is not limited to a primary care clinician, ob/gyn, pediatrician, infectious diseases specialist)

      *Potent antiretroviral therapy is described as any antiretroviral therapy that has demonstrated optimal efficacy and results in durable suppression of HIV as shown by prior clinical trials

    • Exclusions

      None

    • Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed Infectious Disease Endorsement Maintenance Project
      Initial Endorsement
      Last Updated
      Removal Date
    • Steward
      National Committee for Quality Assurance
      Steward Organization POC Email
      [email protected]
      Steward Organization Copyright

      This Measure, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposed, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, (on behalf of the Consortium) or NCQA. Neither the AMA, NCQA, Consortium nor its members shall be responsible for any use of the Measure.

      © 2012 American Medical Association and National Committee for Quality Assurance. All Rights Reserved

      Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.